期刊文献+

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology 预览

在线阅读 下载PDF
分享 导出
摘要 Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.
出处 《癌症生物学与医学:英文版》 CAS CSCD 2019年第1期189-204,共16页 Cancer Biology & Medicine
基金 grants from Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120) General Research Project of Guangzhou Science and Technology Bureau (Grant No. 201607010391) National Key Research and Development Program of China (Grant No. 2016YFC1303800) Guangdong Provincial Applied S&T R&D Program (Grant No. 2016B020237006).
作者简介 Correspondence to:Xuchao Zhang,E-mail:zhxuchao3000@126.com;Correspondence to:Yilong Wu ,E-mail:syylwu@live.cn.
  • 相关文献
投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈